A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: details revised at 8 of 8 entries
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2025 to Aug 19, 2025
    • Eligibility criteria expanded, about 45 words
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blind, placebo-controlled, multiple-ascending-dose study of SN2001 in healthy adult subjects. The study is designed to evaluate the safety, tolerability and immunogenicity of SN2001.
Trial Details
NCT Number NCT07059403
Lead Sponsor Chimivac INC
Conditions
(from sponsor)		 Chronic Hepatitis B Infection
Related terms Hepatitis B, Hepatitis B, Chronic
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov